Table 1.
Patient characteristics of 63 patients with IBD-associated colorectal carcinoma
| Number of total: 63 pts | Ulcerative colitis (n = 50) | Crohn disease (n = 13) | |
|---|---|---|---|
| Sex (M/F) | 29/21 | 6/7 | P = 0.444 |
| Alter | 49.0 (± 16.7) | 43.2 (± 9.9) | P = 0.132 |
| BMI | 27.9 ± 11 | 22.6 ± 3.6 | P = 0.173 |
| Smoking (> 5 Py) | 1 (0.2%) | 4 (30%) | P = 0.004 |
| Years of disease | 18.5 (± 9.9) | 19.0 (± 5.9) | P = 0.812 |
| Surveillance colonoscopy performed | 42 (84%) | 13 (100%) | P = 0.333 |
| Presence of DALM | 30 (60%) | 5 (38.4%) | P = 0.257 |
| Cortison dependance | 14 (28%) | 6 (46%) | P = 0.245 |
| Immunotherapy | 1 (0.2%) | 1 (7%) | P = 0.298 |
| 5-ASA therapy | 33 (66%) | 8 (61.5%) | P = 0.400 |
| Immunosuppression | 9 (18%) | 5 (38%) | P = 0.153 |
| MSI | 5 (1%) | 4 (30%) | P = 0.072 |
| Active disease | 49 (98%) | 13 (100%) | P = 0.251 |
| PSC | 8 (1.6%) | 4 (30%) | P = 0.486 |
| Chemotherapy | 24 (48%) | 11 (84.6%) | P = 0.124 |
| Immunotherapy | 1 (0.2%) | 1 (7.7%) | P = 0.291 |
| Double colorectal cancer | 5 (1%) | 1 (7.7%) | P = 0.800 |
| Stenosis | 31 (62%) | 7 (53.8%) | P = 0.591 |
| Synchronous inflammation and cancer | 37 (74%) | 10 (77%) | P = 0.842 |
| Colitis extension | P < 0.001 | ||
|
- Rectum - Sigmoid colon - Left-sided - Pancolitis - Ileocoeal |
2 5 6 37 0 |
0 2 1 7 3 |
|
BMI body mass index, MSI microsatellite instability, PSC primary sclerosing cholangitis, DALM dysplasia-associated lesion or mass, 5-ASA 5 aminosalicilate, Py pack years